Pediatric attention-deficit/hyperactivity disorder (ADHD) is a common childhood condition that can continue through adolescence and into adulthood. Despite a number of available—and largely efficacious—pharmacological treatments, opportunity exists for emerging agents that offer improvements in efficacy(including alleviating secondary symptom domains, such as executive functioning) and in safety and tolerability, most notably in terms of the risk for abuse and dependence. The high percentage of patients with inadequate progress in controlling ADHD symptoms, coupled with the need for better maintenance over the long term and other areas requiring considerable advancement, poses a large unmet need and ample commercial opportunity for a new drug to improve pediatric ADHD treatment.
- What are surveyed psychiatrists’ opinions of the relative performance of select therapies, including Vyvanse/Elvanse (Shire) and Metadate CD (UCB)/Quasym LP/Equasym Retard/XL (Shire), on key efficacy, safety/tolerability, and convenience of administration attributes?
- What are the top areas of unmet need in pediatric ADHD, and which therapies in development, if any, are poised to meet these needs?
- How much of an improvement would surveyed psychiatrists like to see on the key clinical attributes from emerging therapies versus current therapies?
- What trade-offs in drug price and performance across key drug attributes are surveyed psychiatrists willing to make?
Unmet Need provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.
Markets covered: United States, United Kingdom, France, Germany.
Primary research: Survey of 60 psychiatrists in the United States and 30 psychiatrists in Europe.
Key companies: Eli Lilly, Janssen, Novartis, Shire.
Key drugs: Vyvanse/Elvanse, Concerta, Strattera, Intuniv.
Key metrics included:
- Stated versus derived analysis of U.S. and European physician prescribing behavior.
- Conjoint analysis with U.S. and European physicians, includingamarket simulator.
- Assessment of current drug performance against treatment drivers and goals.
- Physician perceptions of unmet need in disease/subpopulation covered and related diseases/subpopulations.
- Analysis of remaining drug development opportunities.
- Attention-Deficit-Hyperactivity Disorder - Unmet Need - Detailed, Expanded Analysis (US & EU)
Author(s): Audreza Das, P.G. Dip.
Audreza Das is a Senior Analyst in the CNS/Ophthalmology team at Decision Resources Group
She has authored content across indications, including neuropathic pain, age-related macular degeneration, treatment-related depression, painful diabetic neuropathy, and migraine. Ms. Das has previously worked at Novo Nordisk, as a Market Analyst for European markets. Previous experience at a SME, included developing disease competitive landscapes, covering global conferences etc. Ms. Das received her B.E. degree in Biotechnology from Birla Institute of Technology, a deemed university and her P.G. Diploma in Cancer Immunology & Biotechnology from University of Nottingham.